Identification and antimicrobial susceptibilities of Ochrobactrum spp.
Identification and antimicrobial susceptibilities of Ochrobactrum spp.
复制标题
DOI：
10.1016/j.ijmm.2008.06.009
复制
发表时间：
2009-03-01
影响因子：
4.1
通讯作者：
Tomaso, Herbert
中科院分区：
文献类型：
--
作者：
Thoma, Bryan;Straube, Eberhard;Tomaso, Herbert
人类赭杆菌（O.）是一种与布鲁氏菌属密切相关的机会性新兴病原体。由于高表型相似性，用常规生化检测系统对布鲁氏菌和其他褐杆菌进行鉴定和分化是不可靠的。本研究采用Etest （TM）检测103株Ochrobactrum分离株对19种临床相关抗菌药物的敏感性。ochrobacum菌株对β -内酰胺类抗生素高度耐药，对环丙沙星敏感，97.1%的菌株对甲氧苄啶/磺胺甲恶唑敏感。研究还表明，API (R)和BD Phoenix (TM) 100体系的生化反应谱仅能在属水平上用于Ochrobactrum分离物的鉴定。我们的体外数据表明，包括环丙沙星和/或甲氧苄啶/磺胺甲恶唑在内的抗菌剂组合可能对Ochrobactrum感染的经验治疗有用。(C) 2008爱思唯尔有限公司版权所有。
Ochrobactrum (O.) anthropi is an opportunistic emerging pathogen closely related to the genus Brucella. Identification and differentiation from brucellae and other Ochrobactrum spp. using routine biochemical test systems is not reliable due to the high phenotypic similarity. In this study, antibiotic susceptibilities of 103 Ochrobactrum isolates were determined using Etest (TM) for 19 clinically relevant antimicrobial agents. Ochrobactrum strains were highly resistant to beta-lactam antibiotics, susceptible to ciprofloxacin, and 97.1% were susceptible to trimethoprim/sulfamethoxazole. It was also demonstrated that biochemical reaction profiles of the API (R) and BD Phoenix (TM) 100 systems for identifying Ochrobactrum isolates can only be used on the genus level. Our in vitro data suggest that combinations of antimicrobial agents including ciprofloxacin and/or trimethoprim/sulfamethoxazole may be useful for empirical treatment of Ochrobactrum infections. (C) 2008 Elsevier GmbH. All rights reserved.